# Extracorporeal photopheresis therapy for graft-versus-host disease with atypical neurological manifestations: a case report **Authors:** Linda Anelli, Daniele Avenoso PMC · DOI: 10.1007/s00277-026-06971-9 · 2026-03-28 ## TL;DR A patient with unusual neurological symptoms from graft-versus-host disease improved after extracorporeal photopheresis treatment. ## Contribution This case report highlights extracorporeal photopheresis as a potential treatment for atypical neurological GVHD. ## Key findings - The patient's neurological GVHD symptoms resolved after extracorporeal photopheresis. - Uncommon GVHD manifestations may respond to non-standard therapies like photopheresis. ## Abstract Uncommon manifestations of graft-versus-host disease are a clinical challenge due to the absence of clear diagnostic criteria and treatment strategies. Herein, we present the case of a patient with neurological manifestations of GVHD that successfully resolved after extracorporeal photopheresis. ## Linked entities - **Diseases:** graft-versus-host disease (MONDO:0013730) ## Full-text entities - **Genes:** SF3B1 (splicing factor 3b subunit 1) [NCBI Gene 23451] {aka Hsh155, MDS, PRP10, PRPF10, SAP155, SF3b155} - **Diseases:** haematological malignancy (MESH:D009369), ischemic (MESH:D002545), opportunistic infections (MESH:D009894), hepatic involvement (MESH:D056486), motion (MESH:D009041), impaired forehead elevation (MESH:D006259), chronic GVHD (MESH:D000092122), joint stiffness (MESH:C535724), pulmonary fungal infection (MESH:D008172), steroid (MESH:D016114), lichenoid lesions (MESH:D017512), central nervous system (CNS) inflammation (MESH:D007249), MDS (MESH:D009190), GVHD (MESH:D006086), Neurological deficits (MESH:D009461), lichen (MESH:D018459), Liver involvement (MESH:D017093), peripheral facial palsy (MESH:C565028), fungal (MESH:D009181), demyelinating lesions (MESH:D003711), infective (MESH:D007239), Idiopathic facial palsy (MESH:D005158), Oral mucosal involvement (MESH:D013280), facial nerve palsy (MESH:D005155), CMV reactivation (MESH:D003586), fascial/joint restriction with reduced range (MESH:C563219), Bell's palsy (MESH:D020330), facial weakness (MESH:D018908), sclerotic and lichenoid skin manifestations (MESH:D012877), inflammatory damage (MESH:D018746) - **Chemicals:** Alemtuzumab (MESH:D000074323), Ciclosporin (MESH:D016572), SR (MESH:D013324), Steroids (MESH:D013256), ruxolitinib (MESH:C540383), letermovir (MESH:C000588473), Cellex (-), valganciclovir (MESH:D000077562), prednisolone (MESH:D011239) - **Species:** Homo sapiens (human, species) [taxon 9606] --- Source: https://tomesphere.com/paper/PMC13032942